Chronic hepatitis C virus infection: A review for pharmacists

Journal of the American Pharmacists Association

Volumn 47, Issue 4, 2007, Pages 508-520

  Rodis, Jennifer ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Adverse drug effects; Hepatitis c virus; Interferon alfa 2a; Pegylated interferon alfa 2b; Ribavirin

Indexed keywords

ANTIVIRUS AGENT; VIRUS RNA;

DRUG COMBINATION; HEPATITIS C; HUMAN; REVIEW;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; RNA, VIRAL;

EID: 34447567398     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2007.06136     Document Type: Review

References (59)

1. National Institutes of Health. Consensus statement publication: management of hepatitis C. Hepatology. 2002;36:S3-20.
2. McHutchinson JG. Understanding hepatitis C. Am J Manag Care. 2004;10(suppl 2):S21-9.
3. Thomson BJ, Finch RG. Hepatitis C virus infection. Clin Microbiol Infect. 2005;11:86-94.
4. Harris HE, Eldridge KP, Harbour S, et al. The HCV National Register Steering Group. Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type? J Viral Hepat. 2007;14:213-20.
5. Centers for Disease Control. Hepatitis C slide kit. Accessed at www.cdc.gov/ncidod/diseases/hepatitis/slideset/hep-c/hcv-epi-for-distrib-000925. pdf, April 25, 2006.
6. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47:1-39.
7. Vandelli C, Renzo F, Romano L, et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10 year prospective follow-up study. Am J Gastroenterol. 2004;99:855-9.
8. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-62.
9. Department of Health. Hepatitis C strategy for England: August 2002. Available at www.dh.gov.uk/ assetRoot/04/05/95/10/04059510.pdf, October 10, 2006.
10. Alter MJ, Kuhnert WI, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. MMWR Recomm Rep. 2003;52:1-13, 15; quiz CE1-4. Available at www.cdc.gov/mmwr/PDF/rr/rr5203.pdf.
11. U.S. Preventative Services Task Force. Screening for hepatitis C virus infection in adults: recommendation statement. Ann Intern Med. 2004;140:462-4.
12. Kleiner DE. The liver biopsy in chronic hepatitis C: a view from the other side of the needle. Semin Liver Dis. 2005;25:52-64.
13. Pawlotsky JM. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol. 2004;12:96-102.
14. Pawlotsky JM. Current and future concepts in hepatitis C therapy. Semin Liver Dis. 2005;25:72-83.
15. Chisari FV. Unscrambling hepatitis C virus-host interactions. Nature. 2005;436:930-2.
16. Hoofnagle JH. Course and outcomes of hepatitis C. Hepatology. 2002;36:S21-9.
17. Hassoun Z, Willems B, Deslauriers J, et al. Assessment of fatigue in patients with chronic hepatitis C using the Fatigue Impact Scale. Dig Dis Sci. 2002;47:2674-81.
18. Coverdale SA, Khan MH, Byth K, et al. Effects of interferon treatment response on liver complications of chronic hepatitis C: 9 year follow-up study. Am J Gastroenterol. 2004;99:636-44.
19. Kim AI, Saab S. Treatment of hepatitis C. Am J Med. 2005;118:808-15.
20. Lee WM, Dienstag JL, Lindsay KL. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials. 2004;25:472-92.
21. Pegasys [package insert]. Nutley, N.J.: Hoffmann-La Roche; 2004.
22. Peg-Intron [package insert]. Kenilworth, NJ: Schering; 2005.
23. Copegus [package insert]. Nutley, N.J.: Hoffmann-La Roche; 2005.
24. Redbook: pharmacy's fundamental reference. 2006 ed. Thomson Healthcare; 2006.
25. Pegylated interferon alfa-2b. Accessed at www.crlonline.com, November 20, 2006.
26. Pegylated interferon alfa-2a. Accessed at www.crlonline.com, November 20, 2006.
27. Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-65.
28. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-82.
29. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005;436:967-72.
30. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005;5:215-29.
31. Zhou S, Liu R, Baroudy BM, et al. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology. 2003;310:333-42.
32. Bacon BR. Managing hepatitis C. Am J Manag Care. 2004;10:S30-40.
33. Heathcote J, Main J. Treatment of hepatitis C. J Viral Hepat. 2005;12:223-35.
34. Layden-Almer JE, Cotler SJ, Layden TJ. Viral kinetics in the treatment of chronic hepatitis C. J Viral Hepatol. 2006;13:499-504.
35. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131:470-7.
36. Shiffman ML, Hofmann CM, Thompson EB, et al. Relationship between biochemical, virological, and histological response during interferon treatment in chronic hepatitis C. Hepatology. 1997;26:780-5.
37. Shiffman ML, Hofmann CM, Contos MJ, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology. 1999;117:1164-72.
38. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med. 1998;339:1493-9.
39. Shiffman ML, Di Biscegle AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. 2004;126:1015-23.
40. Leevy CB, Ramaraju CP, Blatt LM. End of treatment response for pegylated-interferon plus weight-based ribavirin nonresponders retreated with interferon alfacon-1 plus weightbased ribavirin. Proceedings of Digestive Disease Week: May 15-20, 2004, New Orleans.
41. Kerr M. Daily consensus interferon shows better efficacy against HCV than pegylated interferon. Accessed at www.medscape.com/viewarticle.547344-print, November 20, 2006.
42. Pearlman BL. Hepatitis C treatment update. Am J Med. 2004;117:344-52.
43. Aspinall RJ, Pockros PJ. Review article: the management of side-effects during therapy for hepatitis C. Aliment Pharmacol Ther. 2004;20:917-29.
44. Laffi G, LaVilla G, Pinzani M, et al. Arachidonic acid derivatives and renal function in liver cirrhosis. Semin Nephrol. 1997;17:530-48.
45. Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology. 2004;126:1302-11.
46. Younossi ZM, Ong JP, Collantes R, et al. Darbepoetin alfa for ribavirin-induced anemia in patients with chronic hepatitis C treated with pegylated interferon and ribavirin: a preliminary analysis. Gastroenterology. 2004;126:A666.
47. Strader DB, Wright T, Thomas DL, Seeff LB. AASLD practice guideline: diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147-71.
48. Soza A, Everhart JE, Glramy MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology. 2002;36:1273-9.
49. Juarez-Navarro A, Vera-de-Leon L, Navarro JM, et al. Incidence and severity of infections according to the development of neutropenia during combined therapy with pegylated interferon-alpha-2a plus ribavirin in chronic hepatitis C infection. Methods Find Exp Clin Pharmacol. 2005;27:317-22.
50. Hauser P, Khosia J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002;7:942-7.
51. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alpha. N Engl J Med. 2001;344:961-6.
52. Schramm TM, Lawford BR, Macdonald GA, Cooksley WG. Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust. 2000;173:359-61.
53. Gleason OC, Yates WR. Five cases of interferon-alpha-induced depression treated with antidepressant therapy. Psychosomatics. 1999;40:510-2.
54. Levenson JL, Fallon HJ. Fluoxetine treatment of depression caused by interferon alpha. Am J Gastroenterol. 1993;88:760-1.
55. Dolder NM, Wilhardt MS, Morreale AP. Justifying a multidisciplinary high-intensity hepatitis C clinic by using decision analysis. Am J Health Syst Pharm. 2002;59:867-71.
56. McHutchinson JG, Barthenschlager R, Patel K, Pawlostsky JM. The face of future hepatitis C antiviral drug development: recent biological and virological advances and their translation to drug development and clinical practice. J Hepatol. 2006;44:411-21.
57. Bretner M. Existing and future therapeutic options for hepatitis C virus infection. Acta Biochim Pol. 2005;52:57-70.
58. De Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature. 2005;436:953-60.
59. ClinicalTrials.gov. Accessed at www.clinicaltrials.gov/ct, September 10, 2006.